Search

Your search keyword '"Kuntz, Jennifer L"' showing total 188 results
Start Over Author "Kuntz, Jennifer L"
188 results on '"Kuntz, Jennifer L"'

1. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

Author

Ellingson, Katherine D., Hollister, James, Porter, Cynthia J., Khan, Sana M., Feldstein, Leora R., Naleway, Allison L., Gaglani, Manjusha, Caban-Martinez, Alberto J., Tyner, Harmony L., Lowe, Ashley A., Olsho, Lauren E.W., Meece, Jennifer, Yoon, Sarang K., Mak, Josephine, Kuntz, Jennifer L., Solle, Natasha Schaefer, Respet, Karley, Baccam, Zoe, Wesley, Meredith G., Thiese, Matthew S., Yoo, Young M., Odean, Marilyn J., Miiro, Flavia N., Pickett, Steve L., Phillips, Andrew L., Grant, Lauren, Romine, James K., Herring, Meghan K., Hegmann, Kurt T., Lamberte, Julie Mayo, Sokol, Brian, Jovel, Krystal S., Thompson, Mark G., Rivers, Patrick, Pilishvili, Tamara, Lutrick, Karen, Burgess, Jefferey L., Midgley, Claire M., and Fowlkes, Ashley L.

Subjects
Diseases -- Relapse, Medical personnel -- Statistics -- Health aspects, Health
Abstract

Essential and frontline workers experience repeated occupational exposure to SARS-CoV-2 (1). The variant B.1.1.529 (Omicron) is characterized by unprecedented transmissibility and potential for immune evasion, which led to a surge [...]

Published
2023
Full Text
View/download PDF

3. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

Author

Hollister, James, Caban-Martinez, Alberto J., Ellingson, Katherine D., Beitel, Shawn, Fowlkes, Ashley L., Lutrick, Karen, Tyner, Harmony L., Naleway, Allison L., Yoon, Sarang K., Gaglani, Manjusha, Hunt, Danielle, Meece, Jennifer, Mayo Lamberte, Julie, Schaefer Solle, Natasha, Rose, Spencer, Dunnigan, Kayan, Khan, Sana M., Kuntz, Jennifer L., Fisher, Julia M., Coleman, Alissa, Britton, Amadea, Thiese, Matthew S., Hegmann, Kurt T., Pavuk, Marian, Ramadan, Ferris A., Fuller, Sammantha, Nematollahi, Amy, Sprissler, Ryan, and Burgess, Jefferey L.

Published
2023
Full Text
View/download PDF

7. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19:A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States

Author

Lo Re III, Vincent, Cocoros, Noelle M., Hubbard, Rebecca A., Dutcher, Sarah K., Newcomb, Craig W., Connolly, John G., Perez-Vilar, Silvia, Carbonari, Dena M., Kempner, Maria E., Hernandez-Munoz, Jose J., Petrone, Andrew B., Pishko, Allyson M., Driscoll, Meighan E. Rogers, Brash, James, Burnett, Sean, Cohet, Catherine, Dahl, Matthew, Defor, Terese A., Delmestri, Antonella, Djibo, Djeneba Audrey, Duarte-Salles, Talita, Harrington, Laura, Kampman, Melissa, Kuntz, Jennifer L., Kurz, Xavier, Mercade-Besora, Nuria, Pawloski, Pamala A., Rijnbeek, Peter R., Seager, Sarah, Steiner, Claudia A., Verhamme, Katia, Wu, Fangyun, Zhou, Yunping, Burn, Edward, Paterson, J. Michael, Prieto-Alhambra, Daniel, Lo Re III, Vincent, Cocoros, Noelle M., Hubbard, Rebecca A., Dutcher, Sarah K., Newcomb, Craig W., Connolly, John G., Perez-Vilar, Silvia, Carbonari, Dena M., Kempner, Maria E., Hernandez-Munoz, Jose J., Petrone, Andrew B., Pishko, Allyson M., Driscoll, Meighan E. Rogers, Brash, James, Burnett, Sean, Cohet, Catherine, Dahl, Matthew, Defor, Terese A., Delmestri, Antonella, Djibo, Djeneba Audrey, Duarte-Salles, Talita, Harrington, Laura, Kampman, Melissa, Kuntz, Jennifer L., Kurz, Xavier, Mercade-Besora, Nuria, Pawloski, Pamala A., Rijnbeek, Peter R., Seager, Sarah, Steiner, Claudia A., Verhamme, Katia, Wu, Fangyun, Zhou, Yunping, Burn, Edward, Paterson, J. Michael, and Prieto-Alhambra, Daniel

Abstract

Purpose: Few studies have examined how the absolute risk of thromboembolism with COVID-19 has evolved over time across different countries. Researchers from the European Medicines Agency, Health Canada, and the United States (US) Food and Drug Administration established a collaboration to evaluate the absolute risk of arterial (ATE) and venous thromboembolism (VTE) in the 90 days after diagnosis of COVID-19 in the ambulatory (eg, outpatient, emergency department, nursing facility) setting from seven countries across North America (Canada, US) and Europe (England, Germany, Italy, Netherlands, and Spain) within periods before and during COVID-19 vaccine availability. Patients and Methods: We conducted cohort studies of patients initially diagnosed with COVID-19 in the ambulatory setting from the seven specified countries. Patients were followed for 90 days after COVID-19 diagnosis. The primary outcomes were ATE and VTE over 90 days from diagnosis date. We measured country -level estimates of 90 -day absolute risk (with 95% confidence intervals) of ATE and VTE. Results: The seven cohorts included 1,061,565 patients initially diagnosed with COVID-19 in the ambulatory setting before COVID19 vaccines were available (through November 2020). The 90 -day absolute risk of ATE during this period ranged from 0.11% (0.09- 0.13%) in Canada to 1.01% (0.97-1.05%) in the US, and the 90 -day absolute risk of VTE ranged from 0.23% (0.21-0.26%) in Canada to 0.84% (0.80-0.89%) in England. The seven cohorts included 3,544,062 patients with COVID-19 during vaccine availability (beginning December 2020). The 90 -day absolute risk of ATE during this period ranged from 0.06% (0.06-0.07%) in England to 1.04% (1.01-1.06%) in the US, and the 90 -day absolute risk of VTE ranged from 0.25% (0.24-0.26%) in England to 1.02% (0.99- 1.04%) in the US. Conclusion: There was heterogeneity by country in 90 -day absolute risk of ATE and VTE after ambulatory COVID-19 diagnosis both before and during COVID

Published
2024

8. 1930. Quality of Life among Patients with Community-onset Clostridioides difficile Infection (CDI) without Subsequent Hospitalization

Author

Schmidt, Mark A, primary, Kuntz, Jennifer L, additional, Shuster, Elizabeth, additional, Contreras, Richard, additional, Donald, Judy L, additional, Barreras, Joanna L, additional, Angulo, Fredrick J, additional, Yu, Holly, additional, Gonzalez, Elisa, additional, Zamparo, Joann M, additional, Florea, Ana, additional, and Tartof, Sara Y, additional

Published
2023
Full Text
View/download PDF

9. 705. Burden of Medically-Attended Diarrhea and Clostridioides difficile Infection (CDI) Among Persons in the Community in an Integrated Healthcare Setting, 2016-2021

Author

Tartof, Sara Y, primary, Schmidt, Mark A, additional, Contreras, Richard, additional, Angulo, Fredrick J, additional, Florea, Ana, additional, Barreras, Joanna L, additional, Donald, Judy L, additional, Zamparo, Joann M, additional, Ling Grant, Deborah S, additional, Shuster, Elizabeth, additional, Gonzalez, Elisa, additional, and Kuntz, Jennifer L, additional

Published
2023
Full Text
View/download PDF

11. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design

Author

Babu, Tara M, primary, Feldstein, Leora R, additional, Saydah, Sharon, additional, Acker, Zachary, additional, Boisvert, Cassandra L, additional, Briggs-Hagen, Melissa, additional, Carone, Marco, additional, Casto, Amanda, additional, Cox, Sarah N, additional, Ehmen, Brenna, additional, Englund, Janet A, additional, Fortmann, Stephen P, additional, Frivold, Collrane J, additional, Groom, Holly, additional, Han, Peter D, additional, Kuntz, Jennifer L, additional, Lockwood, Tina, additional, Midgley, Claire M, additional, Mularski, Richard A, additional, Ogilvie, Tara, additional, Reich, Sacha L, additional, Schmidt, Mark A, additional, Smith, Ning, additional, Starita, Lea, additional, Stone, Jeremy, additional, Vandermeer, Meredith, additional, Weil, Ana A, additional, Wolf, Caitlin R, additional, Chu, Helen Y, additional, and Naleway, Allison L, additional

Published
2023
Full Text
View/download PDF

12. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study

Author

Lo Re, Vincent, primary, Dutcher, Sarah K, additional, Connolly, John G, additional, Perez-Vilar, Silvia, additional, Carbonari, Dena M, additional, DeFor, Terese A, additional, Djibo, Djeneba Audrey, additional, Harrington, Laura B, additional, Hou, Laura, additional, Hennessy, Sean, additional, Hubbard, Rebecca A, additional, Kempner, Maria E, additional, Kuntz, Jennifer L, additional, McMahill-Walraven, Cheryl N, additional, Mosley, Jolene, additional, Pawloski, Pamala A, additional, Petrone, Andrew B, additional, Pishko, Allyson M, additional, Rogers Driscoll, Meighan, additional, Steiner, Claudia A, additional, Zhou, Yunping, additional, and Cocoros, Noelle M, additional

Published
2023
Full Text
View/download PDF

13. Burden of Medically Attended Diarrhea and Outpatient Clostridioides difficile Infection Among Persons in 2 Large Integrated Healthcare Settings, 2016–2021.

Author

Tartof, Sara Y, Schmidt, Mark A, Contreras, Richard, Angulo, Frederick J, Florea, Ana, Barreras, Joanna L, Donald, Judy, Zamparo, Joann, Grant, Deborah Ling, Shuster, Elizabeth, Gonzalez, Elisa, and Kuntz, Jennifer L

Subjects
CLOSTRIDIOIDES difficile, OVERWEIGHT persons, DIARRHEA, NOSOLOGY, MEDICAL care
Abstract

Background Identification of Clostridioides difficile infection (CDI) in the community setting is increasing. We describe testing for CDI among patients with medically attended diarrhea (MAD) in the outpatient setting, and the incidence of outpatient CDI. Methods This was a retrospective cohort study among members ≥18 years of age from Kaiser Permanente Southern California and Kaiser Permanente Northwest from 1 January 2016 through 31 December 2021. MAD was identified by outpatient diarrheal International Classification of Diseases, Tenth Revision diagnosis codes, and CDI through positive laboratory results. Outpatient CDI was defined by no hospitalization ≤7 days after specimen collection. Incidence rates (IRs) of outpatient CDI were stratified by select demographic and clinical variables. Outpatient CDI burden 12 months following index date was measured by CDI-associated healthcare visits, and CDI testing and treatment. Results We identified 777 533 MAD episodes; 12.1% (93 964/777 533) were tested for CDI. Of those tested, 10.8% (10 110/93 964) were positive. Outpatient CDI IR was 51.0 (95% confidence interval [CI], 49.8–52.2) per 100 000 person-years, decreasing from 58.2 (95% CI, 55.7–60.7) in 2016 to 45.7 (95% CI, 43.7–47.8) in 2021. Approximately 44% (n = 4200) received an antibiotic 30 days prior to index date and 84.1% (n = 8006) CDIs were "community-associated" (no hospitalizations 12 weeks prior to index date). Of outpatient CDIs, 6.7% (n = 526) had a CDI-associated hospitalization ≤12 months. Conclusions There was a high incidence of outpatient CDI despite infrequent CDI testing among patients with MAD. The majority of those with outpatient CDI had no recent antibiotic use and no recent hospitalization. Further studies are needed to understand the source and management of medically attended outpatient CDI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. CASCADIA: A prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults utilizing a remote nasal swab collection and web-based survey design

Author

Babu, Tara M., primary, Feldstein, Leora R., additional, Saydah, Sharon, additional, Acker, Zachary, additional, Boisvert, Cassandra L., additional, Briggs-Hagen, Melissa, additional, Carone, Marco, additional, Casto, Amanda, additional, Cox, Sarah N., additional, Ehmen, Brenna, additional, Englund, Janet A., additional, Fortmann, Stephen P., additional, Frivold, Collrane J., additional, Groom, Holly, additional, Han, Peter, additional, Kuntz, Jennifer L., additional, Lockwood, Tina, additional, Midgley, Claire M., additional, Mularski, Richard A., additional, Ogilvie, Tara, additional, Reich, Sacha, additional, Schmidt, Mark A., additional, Smith, Ning, additional, Starita, Lea, additional, Stone, Jeremy, additional, Vandermeer, Meredith, additional, Weil, Ana A., additional, Wolf, Caitlin R., additional, Chu, Helen Y., additional, and Naleway, Allison L., additional

Published
2023
Full Text
View/download PDF

16. Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses

Author

Herring, Meghan K, primary, Romine, James K, additional, Wesley, Meredith G, additional, Ellingson, Katherine D, additional, Yoon, Sarang K, additional, Caban-Martinez, Alberto J, additional, Meece, Jennifer, additional, Gaglani, Manjusha, additional, Grant, Lauren, additional, Olsho, Lauren E W, additional, Tyner, Harmony L, additional, Naleway, Allison L, additional, Khan, Sana M, additional, Phillips, Andrew L, additional, Solle, Natasha Schaefer, additional, Rose, Spencer, additional, Mak, Josephine, additional, Fuller, Sammantha B, additional, Hunt, Angela, additional, Kuntz, Jennifer L, additional, Beitel, Shawn, additional, Yoo, Young M, additional, Zheng, Pearl Q, additional, Arani, Gayatri, additional, Lamberte, Julie Mayo, additional, Edwards, Taylor, additional, Thompson, Mark G, additional, Sprissler, Ryan, additional, Thornburg, Natalie J, additional, Lowe, Ashley A, additional, Pilishvili, Tamara, additional, Uhrlaub, Jennifer L, additional, Lutrick, Karen, additional, Burgess, Jefferey L, additional, and Fowlkes, Ashley L, additional

Published
2022
Full Text
View/download PDF

18. Patient-centered interventions to improve medication management and adherence: A qualitative review of research findings

Author

Kuntz, Jennifer L., Safford, Monika M., Singh, Jasvinder A., Phansalkar, Shobha, Slight, Sarah P., Her, Qoua Liang, Lapointe, Nancy Allen, Mathews, Robin, O’Brien, Emily, Brinkman, William B., Hommel, Kevin, Farmer, Kevin C., Klinger, Elissa, Maniam, Nivethietha, Sobko, Heather J., Bailey, Stacy C., Cho, Insook, Rumptz, Maureen H., Vandermeer, Meredith L., and Hornbrook, Mark C.

Published
2014
Full Text
View/download PDF

19. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients

Author

Lo Re, Vincent, primary, Dutcher, Sarah K., additional, Connolly, John G., additional, Perez-Vilar, Silvia, additional, Carbonari, Dena M., additional, DeFor, Terese A., additional, Djibo, Djeneba Audrey, additional, Harrington, Laura B., additional, Hou, Laura, additional, Hennessy, Sean, additional, Hubbard, Rebecca A., additional, Kempner, Maria E., additional, Kuntz, Jennifer L., additional, McMahill-Walraven, Cheryl N., additional, Mosley, Jolene, additional, Pawloski, Pamala A., additional, Petrone, Andrew B., additional, Pishko, Allyson M., additional, Driscoll, Meighan Rogers, additional, Steiner, Claudia A., additional, Zhou, Yunping, additional, and Cocoros, Noelle M., additional

Published
2022
Full Text
View/download PDF

20. Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study

Author

Burns, Joy, primary, Rivers, Patrick, additional, LeClair, Lindsay B, additional, Jovel, Krystal S, additional, Rai, Ramona P, additional, Lowe, Ashley A, additional, Edwards, Laura J, additional, Khan, Sana M, additional, Mathenge, Clare, additional, Ferraris, Maria, additional, Kuntz, Jennifer L, additional, Lamberte, Julie Mayo, additional, Hegmann, Kurt T, additional, Odean, Marilyn J, additional, McLeland-Wieser, Hilary, additional, Beitel, Shawn, additional, Odame-Bamfo, Leah, additional, Schaefer Solle, Natasha, additional, Mak, Josephine, additional, Phillips, Andrew L, additional, Sokol, Brian E, additional, Hollister, James, additional, Ochoa, Jezahel S, additional, Grant, Lauren, additional, Thiese, Matthew S, additional, Jacoby, Keya B, additional, Lutrick, Karen, additional, Pubillones, Felipe A, additional, Yoo, Young M, additional, Rentz Hunt, Danielle, additional, Ellingson, Katherine, additional, Berry, Mark C, additional, Gerald, Joe K, additional, Lopez, Joanna, additional, Gerald, Lynn B, additional, Wesley, Meredith G, additional, Krupp, Karl, additional, Herring, Meghan K, additional, Madhivanan, Purnima, additional, Caban-Martinez, Alberto J, additional, Tyner, Harmony L, additional, Meece, Jennifer K, additional, Yoon, Sarang K, additional, Fowlkes, Ashley L, additional, Naleway, Allison L, additional, Gwynn, Lisa, additional, Burgess, Jefferey L, additional, Thompson, Mark G, additional, Olsho, Lauren EW, additional, and Gaglani, Manjusha, additional

Published
2022
Full Text
View/download PDF

22. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers-- Eight U.S. Locations, December 2020-March 2021

Author

Thompson, Mark G., Burgess, Jefferey L., Naleway, Allison L., Tyner, Harmony L., Yoon, Sarang K., Meece, Jennifer, Olsho, Lauren E.W., Caban-Martinez, Alberto J., Fowlkes, Ashley, Lutrick, Karen, Kuntz, Jennifer L., Dunnigan, Kayan, Odean, Marilyn J., Hegmann, Kurt T., Stefanski, Elisha, Edwards, Laura J., Schaefer-Solle, Natasha, Grant, Lauren, Ellingson, Katherine, Groom, Holly C., Zunie, Tnelda, Thiese, Matthew S., Ivacic, Lynn, Wesley, Meredith G., Lamberte, Julie Mayo, Sun, Xiaoxiao, Smith, Michael E., Phillips, Andrew L., Groover, Kimberly D., Yoo, Young M., Gerald, Joe, Brown, Rachel T., Herring, Meghan K., Joseph, Gregory, Beitel, Shawn, Morrill, Tyler C., Mak, Josephine, Rivers, Patrick, Harris, Katherine M., Hunt, Danielle R., Arvay, Melissa L., Kutty, Preeta, Fry, Alicia M., and Gaglani, Manjusha

Subjects
Pfizer Inc., Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Messenger RNA -- Health aspects, Infection -- Health aspects, Vaccines -- Health aspects, Medical personnel -- Health aspects, Evidence-based medicine -- Health aspects, Pharmaceutical industry -- Health aspects, Health, Comirnaty (Vaccine) -- Health aspects
Abstract

On March 29, 2021, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr) Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been [...]

Published
2021

23. Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses.

Author

Herring, Meghan K, Romine, James K, Wesley, Meredith G, Ellingson, Katherine D, Yoon, Sarang K, Caban-Martinez, Alberto J, Meece, Jennifer, Gaglani, Manjusha, Grant, Lauren, Olsho, Lauren E W, Tyner, Harmony L, Naleway, Allison L, Khan, Sana M, Phillips, Andrew L, Solle, Natasha Schaefer, Rose, Spencer, Mak, Josephine, Fuller, Sammantha B, Hunt, Angela, and Kuntz, Jennifer L

Subjects
SARS-CoV-2, IMMUNOGLOBULINS, CONFIDENCE intervals, IMMUNIZATION, RESEARCH methodology, REGRESSION analysis, INFECTION, COMPARATIVE studies, MESSENGER RNA, RESEARCH funding, DATA analysis software, LONGITUDINAL method
Abstract

Background Data on antibody kinetics are limited among individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From a cohort of healthcare personnel and other frontline workers in 6 US states, we assessed antibody waning after messenger RNA (mRNA) dose 2 and response to dose 3 according to SARS-CoV-2 infection history. Methods Participants submitted sera every 3 months, after SARS-CoV-2 infection, and after each mRNA vaccine dose. Sera were tested for antibodies and reported as area under the serial dilution curve (AUC). Changes in AUC values over time were compared using a linear mixed model. Results Analysis included 388 participants who received dose 3 by November 2021. There were 3 comparison groups: vaccine only with no known prior SARS-CoV-2 infection (n = 224); infection prior to dose 1 (n = 123); and infection after dose 2 and before dose 3 (n = 41). The interval from dose 2 and dose 3 was approximately 8 months. After dose 3, antibody levels rose 2.5-fold (95% confidence interval [CI] = 2.2–3.0) in group 2 and 2.9-fold (95% CI = 2.6–3.3) in group 1. Those infected within 90 days before dose 3 (and median 233 days [interquartile range, 213–246] after dose 2) did not increase significantly after dose 3. Conclusions A third dose of mRNA vaccine typically elicited a robust humoral immune response among those with primary vaccination regardless of SARS-CoV-2 infection >3 months prior to boosting. Those with infection <3 months prior to boosting did not have a significant increase in antibody concentrations in response to a booster. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study (Preprint)

Author

Burns, Joy, primary, Rivers, Patrick, additional, LeClair, Lindsay B, additional, Jovel, Krystal, additional, Rai, Ramona P, additional, Lowe, Ashley A, additional, Edwards, Laura J, additional, Khan, Sana M, additional, Mathenge, Clare, additional, Ferraris, Maria, additional, Kuntz, Jennifer L, additional, Lambert, Julie Mayo, additional, Hegmann, Kurt T, additional, Odean, Marilyn J, additional, McLeland-Wieser, Hilary, additional, Beitel, Shawn, additional, Odame-Bamfo, Leah, additional, Schaefer Solle, Natasha, additional, Mak, Josephine, additional, Phillips, Andrew L, additional, Sokol, Brian E, additional, Hollister, James, additional, Ochoa, Jezahel S, additional, Grant, Lauren, additional, Thiese, Matthew S, additional, Jacoby, Keya B, additional, Lutrick, Karen, additional, Pubillones, Felipe A, additional, Young, Yoo M, additional, Rentz Hunt, Danielle, additional, Ellingson, Katherine, additional, Berry, Mark C, additional, Gerald, Joe K, additional, Lopez, Joanna, additional, Gerald, Lynn, additional, Wesley, Meredith G, additional, Krupp, Karl, additional, Herring, Meghan K, additional, Madhivanan, Purnima, additional, Caban-Martinez, Alberto J, additional, Tyner, Harmony L, additional, Meece, Jennifer K, additional, Yoon, Sarang K, additional, Fowlkes, Ashley L, additional, Naleway, Allison L, additional, Gwynn, Lisa, additional, Burgess, Jefferey L, additional, Thompson, Mark G, additional, Olsho, Lauren EW, additional, and Gaglani, Manjusha, additional

Published
2022
Full Text
View/download PDF

31. Incidence of SARS‐CoV‐2 infection among COVID‐19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January–September 2021

Author

Naleway, Allison L., primary, Grant, Lauren, additional, Caban‐Martinez, Alberto J., additional, Wesley, Meredith G., additional, Burgess, Jefferey L., additional, Groover, Kimberly, additional, Gaglani, Manjusha, additional, Yoon, Sarang K., additional, Tyner, Harmony L., additional, Meece, Jennifer, additional, Kuntz, Jennifer L., additional, Yoo, Young M., additional, Schaefer‐Solle, Natasha, additional, Olsho, Lauren E. W., additional, Gerald, Joe K., additional, Rose, Spencer, additional, Thiese, Matthew S., additional, Lundgren, Jessica, additional, Groom, Holly C., additional, Mak, Josephine, additional, Louzado Feliciano, Paola, additional, Edwards, Laura J., additional, Lutrick, Karen, additional, Dunnigan, Kayan, additional, Phillips, Andrew L., additional, Lamberte, Julie Mayo, additional, Noriega, Roger, additional, Sokol, Brian E., additional, Odean, Marilyn, additional, Ellingson, Katherine D., additional, Smith, Michael, additional, Hegmann, Kurt T., additional, Respet, Karley, additional, Dickerson, Monica, additional, Cruz, Alexandra, additional, Fleary, Deanna E., additional, Murthy, Kempapura, additional, Hunt, Angela, additional, Azziz‐Baumgartner, Eduardo, additional, Gallimore‐Wilson, Damena, additional, Harder, Jenna A., additional, Odame‐Bamfo, Leah, additional, Viergutz, Jennifer, additional, Arvay, Melissa, additional, Jones, John M., additional, Mistry, Peenaz, additional, Thompson, Mark G., additional, and Fowlkes, Ashley L., additional

Published
2022
Full Text
View/download PDF

32. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection

Author

Tyner, Harmony L, primary, Burgess, Jefferey L, additional, Grant, Lauren, additional, Gaglani, Manjusha, additional, Kuntz, Jennifer L, additional, Naleway, Allison L, additional, Thornburg, Natalie J, additional, Caban-Martinez, Alberto J, additional, Yoon, Sarang K, additional, Herring, Meghan K, additional, Beitel, Shawn C, additional, Blanton, Lenee, additional, Nikolich-Zugich, Janko, additional, Thiese, Matthew S, additional, Pleasants, Jessica Flores, additional, Fowlkes, Ashley L, additional, Lutrick, Karen, additional, Dunnigan, Kayan, additional, Yoo, Young M, additional, Rose, Spencer, additional, Groom, Holly, additional, Meece, Jennifer, additional, Wesley, Meredith G, additional, Schaefer-Solle, Natasha, additional, Louzado-Feliciano, Paola, additional, Edwards, Laura J, additional, Olsho, Lauren E W, additional, and Thompson, Mark G, additional

Published
2021
Full Text
View/download PDF

33. Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): Protocol for a Multisite Longitudinal Cohort Study

Author

Edwards, Laura J, primary, Fowlkes, Ashley L, additional, Wesley, Meredith G, additional, Kuntz, Jennifer L, additional, Odean, Marilyn J, additional, Caban-Martinez, Alberto J, additional, Dunnigan, Kayan, additional, Phillips, Andrew L, additional, Grant, Lauren, additional, Herring, Meghan K, additional, Groom, Holly C, additional, Respet, Karley, additional, Beitel, Shawn, additional, Zunie, Tnelda, additional, Hegmann, Kurt T, additional, Kumar, Archana, additional, Joseph, Gregory, additional, Poe, Brandon, additional, Louzado-Feliciano, Paola, additional, Smith, Michael E, additional, Thiese, Matthew S, additional, Schaefer-Solle, Natasha, additional, Yoo, Young M, additional, Silvera, Carlos A, additional, Mayo Lamberte, Julie, additional, Mak, Josephine, additional, McDonald, L Clifford, additional, Stuckey, Matthew J, additional, Kutty, Preeta, additional, Arvay, Melissa L, additional, Yoon, Sarang K, additional, Tyner, Harmony L, additional, Burgess, Jefferey L, additional, Hunt, Danielle Rentz, additional, Meece, Jennifer, additional, Gaglani, Manjusha, additional, Naleway, Allison L, additional, and Thompson, Mark G, additional

Published
2021
Full Text
View/download PDF

34. Trimethoprim–sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies†

Author

Hansen, Craig, Andrade, Susan E., Freiman, Heather, Dublin, Sascha, Haffenreffer, Katie, Cooper, William O., Cheetham, Craig T., Toh, Sengwee, Li, De-Kun, Raebel, Marsha A., Kuntz, Jennifer L., Perrin, Nancy, Rosales, Gabriela A., Carter, Shelley, Pawloski, Pamala A., Maloney, Elizabeth M., Graham, David J., Sahin, Leyla, Scott, Pamela E., Yap, John, and Davis, Robert

Published
2016
Full Text
View/download PDF

35. RESEARCH “I really had somebody in my corner.” Patient experiences with a pharmacist-led opioid tapering program.

Author

Schneider, Jennifer L., Firemark, Alison J., Papajorgji-Taylor, Dea, Reese, Katherine R., Thorsness, Lou Ann, Sullivan, Mark D., DeBar, Lynn L., Smith, David H., and Kuntz, Jennifer L.

Subjects
PATIENTS' attitudes, MEDICAL personnel, INTEGRATED health care delivery, OPIOIDS, COMPARATIVE method
Abstract

Background: Opioid tapering has been identified as an effective strategy to prevent the dangers associated with long-term opioid therapy for patients with chronic pain. However, many patients are resistant to tapering, and conversations about tapering can be challenging for health care providers. Pharmacists can play a role in supporting both providers and patients with the process of opioid tapering. Objective: Qualitatively describe patient experiences with a unique phone-based and pharmacy-led opioid tapering program implemented within an integrated health care system. Methods: In-depth telephone interviews with patients who completed the programwere recorded, transcribed, and analyzed. Themeswere identified through a constant comparative approach. Results: We completed 25 interviews; 80% of patients were women (20), with a mean age of 58 years, and 72% (18) had been using opioids for pain management for 10 or moreyears. Most (60%) described a positive and satisfying experience with the tapering program. Strengths of the program reported by patients included a patient-centered and compassionate taper approach, flexible taper pace, easy access to knowledgeable pharmacist advocates, and resultant improvements in quality of life (e.g., increased energy). Challenges reported included: unhelpful or difficult-to-access nonpharmacological pain management options, negative quality of life impacts (e.g., inability to exercise), and lack of choice in the taper process. At the end of tapering, most patients (72%) described their pain as reduced or manageable rather than worse and expressed willingness to use the program in the future if a need should arise. Conclusions: Patients in a pharmacist-led opioid tapering program appreciated the program’s individualized approach to care and access to pharmacist’ expertise. Most interviewed patients successfully reduced their opioid use and recommended that the program should continue as an offered service. To improve the program, patients suggested increased personalization of the taper process and additional support for withdrawal symptoms and nonpharmacological pain management. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. High Burden of COVID-19 among Unvaccinated Law Enforcement Officers and Firefighters

Author

Caban-Martinez, Alberto J., primary, Gaglani, Manjusha, additional, Olsho, Lauren E.W., additional, Grant, Lauren, additional, Schaefer-Solle, Natasha, additional, Tyner, Harmony L., additional, Yoon, Sarang K., additional, Naleway, Allison L., additional, Lutrick, Karen, additional, Meec, Jennifer, additional, Odean, Marilyn, additional, Thiese, Matthew S., additional, Kuntz, Jennifer L., additional, Rose, Spencer, additional, Wesley, Meredith G., additional, Ellingson, Katherine D., additional, Mak, Josephine, additional, Louzado-Feliciano, Paola, additional, Respet, Karley, additional, Phillips, Andrew L., additional, Groom, Holly C., additional, Dunnigan, Kayan, additional, Groover, Kimberly, additional, Gerald, Joe K., additional, Yoo, Young M., additional, Noriega, Roger, additional, Lundgrenn, Jessica, additional, Hegmann, Kurt T., additional, Smith, Michael, additional, Mayo Lamberte, Julie, additional, Cruz, Alexandra, additional, Hunt, Angela, additional, Bruner, Matthew M., additional, Murthy, Kempapura, additional, Edwards, Laura J., additional, Fowlkes, Ashley L., additional, Gallimore-Wilson, Damena, additional, Viergutz, Jennifer, additional, Brown, Rachel, additional, Odame-Bamfo, Leah, additional, Sokol, Brian E., additional, Dickerson, Monica, additional, Jones, John M., additional, Praggastis, Jenna, additional, Fleary, Deanna E., additional, Kutty, Preeta K., additional, Thompson, Mark G., additional, and Burgess, Jefferey L., additional

Published
2021
Full Text
View/download PDF

37. Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection

Author

Tyner, Harmony L., primary, Burgess, Jefferey L, additional, Grant, Lauren, additional, Gaglani, Manjusha, additional, Kuntz, Jennifer L., additional, Naleway, Allison L., additional, Thornburg, Natalie J., additional, Caban-Martinez, Alberto J., additional, Yoon, Sarang K., additional, Herring, Meghan K., additional, Beitel, Shawn C., additional, Blanton, Lenee, additional, Nikolich-Zugich, Janko, additional, Thiese, Matthew S., additional, Pleasants, Jessica Flores, additional, Fowlkes, Ashley L., additional, Lutrick, Karen, additional, Dunnigan, Kayan, additional, M.Yoo, Young, additional, Rose, Spencer, additional, Groom, Holly, additional, Meece, Jennifer, additional, Wesley, Meredith G., additional, Schaefer-Solle, Natasha, additional, Louzado-Feliciano, Paola, additional, Edwards, Laura J., additional, Olsho, Lauren E. W., additional, and Thompson, Mark G., additional

Published
2021
Full Text
View/download PDF

38. Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin‐converting enzyme inhibitor therapy

Author

Mansi, Elizabeth T., primary, Johnson, Eric S., additional, Thorp, Micah L., additional, Go, Alan S., additional, Lee, Ming‐Sum, additional, Shen, Albert Yuh‐Jer, additional, Park, Ken J., additional, Budzynska, Katarzyna, additional, Markin, Abraham, additional, Sung, Sue Hee, additional, Thompson, Jamie H., additional, Slaughter, Matthew T., additional, Luong, Tiffany Q., additional, An, Jaejin, additional, Reynolds, Kristi, additional, Roblin, Douglas W., additional, Cassidy‐Bushrow, Andrea E., additional, Kuntz, Jennifer L., additional, Schlienger, Raymond G., additional, Behr, Sigrid, additional, and Smith, David H., additional

Published
2021
Full Text
View/download PDF

40. Identification of Stevens–Johnson syndrome and toxic epidermal necrolysis in electronic health record databases†

Author

Davis, Robert L., Gallagher, Mia A., Asgari, Maryam M., Eide, Melody J., Margolis, David J., Macy, Eric, Burmester, James K., Selvam, Nandini, Boscarino, Joseph A., Cromwell, Lee F., Feigelson, Heather S., Kuntz, Jennifer L., Pawloski, Pamala A., Penfold, Robert B., Raebel, Marsha A., Sridhar, Gayathri, Wu, Ann, La Grenade, Lois A., Pacanowski, Michael A., and Pinheiro, Simone P.

Published
2015
Full Text
View/download PDF

41. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Author

Thompson, Mark G., primary, Burgess, Jefferey L., additional, Naleway, Allison L., additional, Tyner, Harmony, additional, Yoon, Sarang K., additional, Meece, Jennifer, additional, Olsho, Lauren E.W., additional, Caban-Martinez, Alberto J., additional, Fowlkes, Ashley L., additional, Lutrick, Karen, additional, Groom, Holly C., additional, Dunnigan, Kayan, additional, Odean, Marilyn J., additional, Hegmann, Kurt, additional, Stefanski, Elisha, additional, Edwards, Laura J., additional, Schaefer-Solle, Natasha, additional, Grant, Lauren, additional, Ellingson, Katherine, additional, Kuntz, Jennifer L., additional, Zunie, Tnelda, additional, Thiese, Matthew S., additional, Ivacic, Lynn, additional, Wesley, Meredith G., additional, Mayo Lamberte, Julie, additional, Sun, Xiaoxiao, additional, Smith, Michael E., additional, Phillips, Andrew L., additional, Groover, Kimberly D., additional, Yoo, Young M., additional, Gerald, Joseph, additional, Brown, Rachel T., additional, Herring, Meghan K., additional, Joseph, Gregory, additional, Beitel, Shawn, additional, Morrill, Tyler C., additional, Mak, Josephine, additional, Rivers, Patrick, additional, Poe, Brandon P., additional, Lynch, Brian, additional, Zhou, Yingtao, additional, Zhang, Jing, additional, Kelleher, Anna, additional, Li, Yan, additional, Dickerson, Monica, additional, Hanson, Erika, additional, Guenther, Kyley, additional, Tong, Suxiang, additional, Bateman, Allen, additional, Reisdorf, Erik, additional, Barnes, John, additional, Azziz-Baumgartner, Eduardo, additional, Hunt, Danielle R., additional, Arvay, Melissa L., additional, Kutty, Preeta, additional, Fry, Alicia M., additional, and Gaglani, Manjusha, additional

Published
2021
Full Text
View/download PDF

42. Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): Protocol for a Multisite Longitudinal Cohort Study (Preprint)

Author

Edwards, Laura J, primary, Fowlkes, Ashley L, additional, Wesley, Meredith G, additional, Kuntz, Jennifer L, additional, Odean, Marilyn J, additional, Caban-Martinez, Alberto J, additional, Dunnigan, Kayan, additional, Phillips, Andrew L, additional, Grant, Lauren, additional, Herring, Meghan K, additional, Groom, Holly C, additional, Respet, Karley, additional, Beitel, Shawn, additional, Zunie, Tnelda, additional, Hegmann, Kurt T, additional, Kumar, Archana, additional, Joseph, Gregory, additional, Poe, Brandon, additional, Louzado-Feliciano, Paola, additional, Smith, Michael E, additional, Thiese, Matthew S, additional, Schaefer-Solle, Natasha, additional, Yoo, Young M, additional, Silvera, Carlos A, additional, Mayo Lamberte, Julie, additional, Mak, Josephine, additional, McDonald, L Clifford, additional, Stuckey, Matthew J, additional, Kutty, Preeta, additional, Arvay, Melissa L, additional, Yoon, Sarang K, additional, Tyner, Harmony L, additional, Burgess, Jefferey L, additional, Hunt, Danielle Rentz, additional, Meece, Jennifer, additional, Gaglani, Manjusha, additional, Naleway, Allison L, additional, and Thompson, Mark G, additional

Published
2021
Full Text
View/download PDF

43. Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

Author

Thompson, Mark G., primary, Burgess, Jefferey L., additional, Naleway, Allison L., additional, Tyner, Harmony, additional, Yoon, Sarang K., additional, Meece, Jennifer, additional, Olsho, Lauren E.W., additional, Caban-Martinez, Alberto J., additional, Fowlkes, Ashley L., additional, Lutrick, Karen, additional, Groom, Holly C., additional, Dunnigan, Kayan, additional, Odean, Marilyn J, additional, Hegmann, Kurt, additional, Stefanski, Elisha, additional, Edwards, Laura J., additional, Schaefer-Solle, Natasha, additional, Grant, Lauren, additional, Ellingson, Katherine, additional, Kuntz, Jennifer L., additional, Zunie, Tnelda, additional, Thiese, Matthew S., additional, Ivacic, Lynn, additional, Wesley, Meredith G., additional, Lamberte, Julie Mayo, additional, Sun, Xiaoxiao, additional, Smith, Michael E., additional, Phillips, Andrew L., additional, Groover, Kimberly D., additional, Yoo, Young M., additional, Gerald, Joe K., additional, Brown, Rachel T., additional, Herring, Meghan K., additional, Joseph, Gregory, additional, Beitel, Shawn, additional, Morrill, Tyler C., additional, Mak, Josephine, additional, Rivers, Patrick, additional, Poe, Brandon P., additional, Lynch, Brian, additional, Zhou, Ying Tao, additional, Zhang, Jing, additional, Kelleher, Anna, additional, Li, Yan, additional, Dickerson, Monica, additional, Hanson, Erika, additional, Guenther, Kyley, additional, Tong, Suxiang, additional, Bateman, Allen, additional, Reisdorf, Erik, additional, Barnes, John, additional, Azziz-Baumgartner, Eduardo, additional, Hunt, Danielle R., additional, Arvay, Melissa L., additional, Kutty, Preeta, additional, Fry, Alicia M., additional, and Gaglani, Manjusha, additional

Published
2021
Full Text
View/download PDF

45. Factors associated with opioid-tapering success: A mixed methods study

Author

Kuntz, Jennifer L., primary, Dickerson, John F., additional, Schneider, Jennifer L., additional, Firemark, Alison J., additional, Papajorgji-Taylor, Dea, additional, Slaughter, Matthew, additional, Reese, Katherine R., additional, Thorsness, Lou Ann, additional, Sullivan, Mark D., additional, Debar, Lynn L., additional, and Smith, David H., additional

Published
2021
Full Text
View/download PDF

46. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection.

Author

Tyner, Harmony L, Burgess, Jefferey L, Grant, Lauren, Gaglani, Manjusha, Kuntz, Jennifer L, Naleway, Allison L, Thornburg, Natalie J, Caban-Martinez, Alberto J, Yoon, Sarang K, Herring, Meghan K, Beitel, Shawn C, Blanton, Lenee, Nikolich-Zugich, Janko, Thiese, Matthew S, Pleasants, Jessica Flores, Fowlkes, Ashley L, Lutrick, Karen, Dunnigan, Kayan, Yoo, Young M, and Rose, Spencer

Subjects
REVERSE transcriptase polymerase chain reaction, IMMUNOGLOBULINS, SARS-CoV-2, COVID-19, CONFIDENCE intervals, COVID-19 vaccines, T-test (Statistics), MESSENGER RNA, DESCRIPTIVE statistics, COVID-19 testing, LONGITUDINAL method
Abstract

Background Data on the development of neutralizing antibodies (nAbs) against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with mRNA COVID-19 vaccines are limited. Methods From a prospective cohort of 3975 adult essential and frontline workers tested weekly from August 2020 to March 2021 for SARS-CoV-2 infection by reverse transcription–polymerase chain reaction assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum-neutralizing antibody titers against USA-WA1/2020-spike pseudotype virus were determined by the 50% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t tests and linear mixed-effects models. Results Among 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93%) developed nAbs with a GMT of 1003 (95% confidence interval, 766–1315). Among 139 previously uninfected participants, 138 (99%) developed nAbs after mRNA vaccine dose 2 with a GMT of 3257 (2596–4052). GMT was higher among those receiving mRNA-1273 vaccine (GMT, 4698; 3186–6926) compared with BNT162b2 vaccine (GMT, 2309; 1825–2919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21 655 (14 766–31 756) after mRNA vaccine dose 1, without further increase after dose 2. Conclusions A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAbs to SARS-CoV-2 than after 1 dose of vaccine or SARS-CoV-2 infection alone. nAb response also differed by mRNA vaccine product. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. A Pharmacist-Led Program to Taper Opioid Use at Kaiser Permanente Northwest: Rationale, Design, and Evaluation

Author

Kuntz, Jennifer L, primary, Schneider, Jennifer L, additional, Firemark, Alison J, additional, Dickerson, John F, additional, Papajorgji-Taylor, Dea, additional, Reese, Katherine R, additional, Hamer, Traci A, additional, Marsh, Darlene, additional, Thorsness, Lou Ann, additional, Sullivan, Mark D, additional, Debar, Lynn L, additional, and Smith, David H, additional

Published
2020
Full Text
View/download PDF

50. Clostridium difficile Infection, Colorado and the Northwestern United States, 2007

Author

Kuntz, Jennifer L., Johnson, Eric S., Raebel, Marsha A., Petrik, Amanda F., Yang, Xiuhai, Thorp, Micah L., Spindel, Steven J., Neil, Nancy, and Smith, David H.

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Infection -- Health aspects, Health
Abstract

Clostridium difficile infection is a major source of illness in the United States (1). Population-based estimates of its incidence tend to include only subsets of infections defined by the setting [...]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results